2-amino-nicotinamide derivatives and their use as VEGF-receptor tyrosine kinase inhibitors

US6624174B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Paul W. Manley · Arlesheim, CH
• Guido Bold · Gipf-Oberfrick, CH

Key dates

• Filing date: Jul 11, 2002
• Grant date: Sep 23, 2003
• Expiry date: Jul 11, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of 2 amino-nicotinamide derivatives of formula I wherein n is from 1 up to and including 6;W is O or S;R1 and R3 represent independently of each other hydrogen, lower alkyl or lower acyl;R2 represents a cycloalkyl group, an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted;R and R′ are independently of each other hydrogen or lower alkyl;X represents an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted;or a N-oxide, a possible tautomer thereof or a pharmaceutically acceptable salt of such a compound, alone or in combination with one or more other pharmaceutically active compounds for the preparation of a pharmaceutical composition for use for therapy of a disease which responds to an inhibitio…